Headlines about Celgene (NASDAQ:CELG) have been trending somewhat positive on Friday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celgene earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.3633043611824 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern’s rankings:
- Why Cable News And Psoriasis Is A Match Made In Advertiser Heaven (finance.yahoo.com)
- Cancer-fighting East Bay company upsizes IPO, raises $120 million – San Francisco Business Times (bizjournals.com)
- Here's Why Shorting Geron Corporation Stock Is a Terrible Idea (finance.yahoo.com)
- Ideaya Biosciences Raises $94M Crossover Series B Financing (finsmes.com)
- Why Biotech Giant Celgene Should Consider Taking Itself Private (finance.yahoo.com)
Shares of Celgene (NASDAQ:CELG) traded down $0.30 during mid-day trading on Friday, reaching $89.61. 14,618,517 shares of the company’s stock traded hands, compared to its average volume of 8,179,740. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. The stock has a market capitalization of $67,950.00, a price-to-earnings ratio of 17.07, a PEG ratio of 0.65 and a beta of 1.58. Celgene has a one year low of $86.55 and a one year high of $147.17.
Celgene declared that its Board of Directors has authorized a stock buyback program on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.
Several research firms have weighed in on CELG. BidaskClub downgraded shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday. Robert W. Baird restated a “hold” rating and set a $92.00 price objective on shares of Celgene in a research note on Thursday, March 1st. Credit Suisse Group set a $129.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Thursday, March 1st. BMO Capital Markets decreased their price objective on shares of Celgene from $144.00 to $139.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Finally, William Blair restated a “buy” rating on shares of Celgene in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $128.22.
In other news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $94.83, for a total transaction of $877,177.50. Following the sale, the director now owns 94,801 shares of the company’s stock, valued at $8,989,978.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark J. Alles purchased 3,260 shares of Celgene stock in a transaction dated Thursday, February 8th. The shares were acquired at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the transaction, the insider now directly owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 41,120 shares of company stock valued at $3,879,509. 0.95% of the stock is currently owned by insiders.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.